The post Ethena Labs cuts ENA’s exchange supply – $0.30 retest possible ONLY IF… appeared on BitcoinEthereumNews.com. With crypto token buybacks at full throttle across the market, Ethena Labs continued its aggressive accumulation of ENA.  That steady purchasing supported price stability, and the team returned to buying again. Ethena Labs adds 25mln ENA According to Onchain Lens, Ethena [ENA] Labs purchased 25 million tokens, valued at $7.05 million, from Bybit. After the latest purchase, the wallet held 779.89 million ENA worth $207.7 million. Source: Onchain Lens On top of that, Ethena Labs’ StablecoinX Inc held 2.146 billion ENA valued at $582.35 million, with a floating profit of $57.8 million. That accumulation suggested continued confidence from the team. Team purchases also reduced the immediate exchange supply, which may support price strength when demand increases. Whales keep buying ENA In addition to Ethena Labs’ purchases, ENA has experienced sustained demand, especially from whale investors.  In fact, Spot Average Order Size data from CryptoQuant showed repeated Large Whale Orders during the past week. Source: CryptoQuant These orders indicated active whale participation. In this case, the cohort accumulated, not distributed. As such, Ethena’s Top Holders Balance Change also remained positive for five consecutive days. A positive Balance Change means Top holders have bought more ENA tokens than they’ve sold.  Source: Nansen In fact, over this period, Top holders have purchased 774.81 million ENA tokens, signaling sustained demand from the cohort.  By contrast, exchange activity aligned with this trend. According to CoinGlass, ENA’s Spot Netflow recorded only one positive reading across the past 10 days. Source: CoinGlass At press time, Spot Netflow stood at -$444.6k, up from -$2.23 million the previous day, indicating continued outflows. Historically, net outflows have aligned with accumulation phases that supported later price strength. Any impact on ENA? Significantly, continued accumulation from whales and Ethena Labs has positively impacted ENA’s price movement. In fact, after successfully holding $0.255… The post Ethena Labs cuts ENA’s exchange supply – $0.30 retest possible ONLY IF… appeared on BitcoinEthereumNews.com. With crypto token buybacks at full throttle across the market, Ethena Labs continued its aggressive accumulation of ENA.  That steady purchasing supported price stability, and the team returned to buying again. Ethena Labs adds 25mln ENA According to Onchain Lens, Ethena [ENA] Labs purchased 25 million tokens, valued at $7.05 million, from Bybit. After the latest purchase, the wallet held 779.89 million ENA worth $207.7 million. Source: Onchain Lens On top of that, Ethena Labs’ StablecoinX Inc held 2.146 billion ENA valued at $582.35 million, with a floating profit of $57.8 million. That accumulation suggested continued confidence from the team. Team purchases also reduced the immediate exchange supply, which may support price strength when demand increases. Whales keep buying ENA In addition to Ethena Labs’ purchases, ENA has experienced sustained demand, especially from whale investors.  In fact, Spot Average Order Size data from CryptoQuant showed repeated Large Whale Orders during the past week. Source: CryptoQuant These orders indicated active whale participation. In this case, the cohort accumulated, not distributed. As such, Ethena’s Top Holders Balance Change also remained positive for five consecutive days. A positive Balance Change means Top holders have bought more ENA tokens than they’ve sold.  Source: Nansen In fact, over this period, Top holders have purchased 774.81 million ENA tokens, signaling sustained demand from the cohort.  By contrast, exchange activity aligned with this trend. According to CoinGlass, ENA’s Spot Netflow recorded only one positive reading across the past 10 days. Source: CoinGlass At press time, Spot Netflow stood at -$444.6k, up from -$2.23 million the previous day, indicating continued outflows. Historically, net outflows have aligned with accumulation phases that supported later price strength. Any impact on ENA? Significantly, continued accumulation from whales and Ethena Labs has positively impacted ENA’s price movement. In fact, after successfully holding $0.255…

Ethena Labs cuts ENA’s exchange supply – $0.30 retest possible ONLY IF…

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

With crypto token buybacks at full throttle across the market, Ethena Labs continued its aggressive accumulation of ENA. 

That steady purchasing supported price stability, and the team returned to buying again.

Ethena Labs adds 25mln ENA

According to Onchain Lens, Ethena [ENA] Labs purchased 25 million tokens, valued at $7.05 million, from Bybit. After the latest purchase, the wallet held 779.89 million ENA worth $207.7 million.

Source: Onchain Lens

On top of that, Ethena Labs’ StablecoinX Inc held 2.146 billion ENA valued at $582.35 million, with a floating profit of $57.8 million.

That accumulation suggested continued confidence from the team.

Team purchases also reduced the immediate exchange supply, which may support price strength when demand increases.

Whales keep buying ENA

In addition to Ethena Labs’ purchases, ENA has experienced sustained demand, especially from whale investors. 

In fact, Spot Average Order Size data from CryptoQuant showed repeated Large Whale Orders during the past week.

Source: CryptoQuant

These orders indicated active whale participation. In this case, the cohort accumulated, not distributed.

As such, Ethena’s Top Holders Balance Change also remained positive for five consecutive days. A positive Balance Change means Top holders have bought more ENA tokens than they’ve sold. 

Source: Nansen

In fact, over this period, Top holders have purchased 774.81 million ENA tokens, signaling sustained demand from the cohort. 

By contrast, exchange activity aligned with this trend. According to CoinGlass, ENA’s Spot Netflow recorded only one positive reading across the past 10 days.

Source: CoinGlass

At press time, Spot Netflow stood at -$444.6k, up from -$2.23 million the previous day, indicating continued outflows.

Historically, net outflows have aligned with accumulation phases that supported later price strength.

Any impact on ENA?

Significantly, continued accumulation from whales and Ethena Labs has positively impacted ENA’s price movement.

In fact, after successfully holding $0.255 support level, Ethena jumped to a local high of $0.28 before slightly retracing. At press time, Ethena [ENA] traded at $0.27, up 8.69% on the daily charts, signaling strong bullish momentum.

Source: TradingView

Even more so, the altcoin’s Relative Vigor Index Zero Cross made a bullish crossover to -0.0096. Although still in a negative zone, it suggested that bulls were slowly gaining control while the market momentum strengthened.

On top of that, Parabolic SAR support sat near $0.2423, serving as the next major downside level.

If buyers maintain momentum, ENA could retest $0.30. A slowdown may push the price toward the SAR support instead.


Final Thoughts

  • ENA’s structure now reflects consistent whale interest and reduced exchange supply, two factors that often matter in volatile markets.
  • Traders will watch whether this accumulation phase marks a turning point or just a temporary pause.
Next: ‘This proposal unfairly targets a single asset class’ — Bitcoin For Corporations challenges MSCI

Source: https://ambcrypto.com/ethena-labs-cuts-enas-exchange-supply-0-30-retest-possible-only-if/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09